August 25, 2011 – Transcatheter structural heart occluder maker Occlutech said this week it closed a 15 million Euro investment in the company to accelerate its device development and bring it to market. The European company develops medical implants to treat structural heart disease such as atrial septal defects and patent foramen ovale (ASD and PFO) and left atrial appendage (LAA) occluders.

August 25, 2011 – Two articles in the Society of Interventional Radiology (SIR)'s flagship publication, the Journal of Vascular and Interventional Radiology, report on studies related to peripheral arterial disease (PAD), coinciding with the approach of September's National PAD Awareness Month.

August 25, 2011 – The U.S. Food and Drug Administration (FDA) has released its list of pre-market approval (PMA) and 510(k) decisions for new or enhanced medical devices from June 2011. The list includes all FDA PMAs, product development protocols (PDP), supplement and notice decisions. This list is generated on a monthly basis.

August 25, 2011 – ­ The Munich biotech company apceth started its first Phase I/II clinical study on somatic cell therapy for advanced peripheral arterial occlusive disease (pAOD) after angioplasty. The aim is to investigate the tolerability and efficacy of somatic cell therapeutics developed by apceth for the treatment of pAOD. The study is designed as an open, randomized, monocenter study with two parallel patient groups and is being conducted in cooperation with the Isar-Medizinzentrum in Munich. The first patients have already been treated. A total of 30 patients are to be recruited into the study by March 2012. The initial results of the study are expected by mid-2012.


August 24, 2011 - The Joint Commission issued an alert today explaining ways to lower risks posed by ionizing radiation from imaging exams while maintaining diagnostic image quality. The Joint Commission said healthcare organizations can reduce risks due to avoidable diagnostic radiation by raising awareness among staff and patients of the increased risks associated with cumulative doses, by providing the right test and dose through effective processes and new technology.

August 24, 2011 — Physio-Control Inc. announced commercial availability of the ReadyLink 12-lead electrocardiogram (ECG) device. It is a new U.S. Food and Drug Administration (FDA) 510(k)-cleared solution designed to improve care for heart attack patients and expand regional ST-segment elevated myocardial infarction (STEMI) systems.

August 24, 2011 — The U.S. Department of Health and Human Services (HHS) announced a new initiative to improve care for patients while in the hospital and after discharge. Doctors, hospitals, and other healthcare providers can now apply for a new program known as the Bundled Payments for Care Improvement initiative (Bundled Payments initiative).

August 24, 2011 -- Radiopharmaceuticals are pharmaceutical agents used to diagnose certain medical problems, such as cardiac, cancer or neurology, and/or treat certain conditions such as cancers. The use of radiopharmaceuticals as tracer dates back to 1930s.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now